Brodalumab (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Brodalumab" in English language version.

refsWebsite

Global rank English rank

10web.archive.org

1^st place

1^st place

2clinicaltrials.gov

5,225^th place

4,062^nd place

2astrazeneca.com

low place

low place

447^th place

338^th place

low place

low place

4^th place

4^th place

68^th place

117^th place

3,257^th place

3,398^th place

1genengnews.com

low place

6,625^th place

low place

low place

1seekingalpha.com

5,344^th place

3,420^th place

ama-assn.org

"Statement On A Nonproprietary Name Adopted By The USAN Council: Brodalumab" (PDF). American Medical Association. Archived (PDF) from the original on 1 February 2016. Retrieved 8 September 2011.

amgen.com

"Amgen to terminate participation in co-development and commercialization of brodaluma" (Press release). Amgen. Archived from the original on 26 May 2015. Retrieved 26 May 2015.

astrazeneca.com

"AstraZeneca and Valeant Pharmaceuticals to partner on brodalumab" (Press release). AstraZeneca. Archived from the original on 4 October 2021. Retrieved 10 June 2022.
"AstraZeneca enters licensing agreements with LEO Pharma in skin diseases" (Press release). AstraZeneca. Archived from the original on 3 October 2021. Retrieved 16 November 2016.

clinicaltrials.gov

Clinical trial number NCT01708590 for "Study of Efficacy, Safety, and Withdrawal and Retreatment With Brodalumab in Moderate to Severe Plaque Psoriasis Subjects (AMAGINE-1)" at ClinicalTrials.gov
Clinical trial number NCT01708629 for "Study of Efficacy and Safety of Brodalumab Compared With Placebo and Ustekinumab in Moderate to Severe Plaque Psoriasis Subjects (AMAGINE-3)" at ClinicalTrials.gov

europa.eu

ema.europa.eu

"Kyntheum EPAR". European Medicines Agency. 17 September 2018. Archived from the original on 13 September 2021. Retrieved 8 June 2022.

fda.gov

nctr-crs.fda.gov

"FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.)". nctr-crs.fda.gov. FDA. Retrieved 22 October 2023.

fda.gov

"FDA approves new psoriasis drug" (Press release). U.S. Food and Drug Administration. 15 February 2017. Archived from the original on 11 December 2019. Retrieved 18 February 2017.

genengnews.com

Philippidis A (26 November 2014). "Brodalumab's No Turkey in Phase III: Amgen and AstraZeneca". Genetic Engineering & Biotechnology News. Archived from the original on 3 December 2014. Retrieved 27 November 2014.

hres.ca

hpr-rps.hres.ca

"Regulatory Decision Summary for Siliq". 23 October 2014. Archived from the original on 7 June 2022. Retrieved 10 June 2022.

nih.gov

dailymed.nlm.nih.gov

"Siliq- brodalumab injection". DailyMed. 12 June 2020. Archived from the original on 18 March 2021. Retrieved 8 June 2022.

seekingalpha.com

House DW (25 January 2016). "FDA accepts AstraZeneca's brodalumab BLA for plaque psoriasis, PDUFA date November 16". Seeking Alpha. Archived from the original on 8 February 2017. Retrieved 10 June 2022.

web.archive.org

"Regulatory Decision Summary for Siliq". 23 October 2014. Archived from the original on 7 June 2022. Retrieved 10 June 2022.
"Siliq- brodalumab injection". DailyMed. 12 June 2020. Archived from the original on 18 March 2021. Retrieved 8 June 2022.
"Kyntheum EPAR". European Medicines Agency. 17 September 2018. Archived from the original on 13 September 2021. Retrieved 8 June 2022.
"Statement On A Nonproprietary Name Adopted By The USAN Council: Brodalumab" (PDF). American Medical Association. Archived (PDF) from the original on 1 February 2016. Retrieved 8 September 2011.
"FDA approves new psoriasis drug" (Press release). U.S. Food and Drug Administration. 15 February 2017. Archived from the original on 11 December 2019. Retrieved 18 February 2017.
Philippidis A (26 November 2014). "Brodalumab's No Turkey in Phase III: Amgen and AstraZeneca". Genetic Engineering & Biotechnology News. Archived from the original on 3 December 2014. Retrieved 27 November 2014.
"Amgen to terminate participation in co-development and commercialization of brodaluma" (Press release). Amgen. Archived from the original on 26 May 2015. Retrieved 26 May 2015.
"AstraZeneca and Valeant Pharmaceuticals to partner on brodalumab" (Press release). AstraZeneca. Archived from the original on 4 October 2021. Retrieved 10 June 2022.
"AstraZeneca enters licensing agreements with LEO Pharma in skin diseases" (Press release). AstraZeneca. Archived from the original on 3 October 2021. Retrieved 16 November 2016.
House DW (25 January 2016). "FDA accepts AstraZeneca's brodalumab BLA for plaque psoriasis, PDUFA date November 16". Seeking Alpha. Archived from the original on 8 February 2017. Retrieved 10 June 2022.